Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“Our study suggests that EPA and DHA (omega-3 fatty acids) induce selective cytotoxic effects in Multiple Myeloma and increase sensitivity to Velcade (bortezomib).”
Multiple myeloma, the blood cancer itself, causes bone, kidney, blood and heart damage. Multiple myeloma therapies cause bone, kidney, blood and heart damage. Most of the time it is impossible for myeloma patients and survivors to tell the difference between damage done by MM symptoms or damage done from MM side effects. Fortunately, omega-3 fatty acids protect against bone, kidney, blood and heart damage whether the damage is caused by the MM itself or the chemotherapy designed to treat your MM.
According to the five studies linked and excerpted below, omega-3 fatty acids:
This blog post signals omega-3 fatty acids joining vitamin D3, curcumin and black seed oil as being evidence-based, non-toxic therapies that treat the most common MM symptoms as well as the most common MM side effects.
Coincidentally (?), blood (infection), bone, kidney and heart damage are also the most common causes of death among multiple myeloma survivors.
Studies confirm that symptoms and side effects can be confused when evaluating newly created chemotherapy regimens. You have to wonder if MM chemotherapy regimens confuse the two…
I take Life Extension Super Omega-3 (Fish Oil) EPA/DHA with Sesame Lignans and Olive Extract- 1 capsule daily. I take this brand because it has been evaluated and approved by Consumerlab.com for purity and efficacy.
To learn more about evidence-based, non-toxic multiple myeloma therapies that treat both MM symptoms and mm side effects, scroll down the page, post a question or a comment and I will reply to you ASAP.
“The n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to enhance the effect of chemotherapeutic drugs in clinical studies in cancer patients and to induce apoptotic tumor cell death in vitro.
Human myeloma cells (L363, OPM-1, OPM-2 and U266) and normal peripheral blood mononuclear cells were exposed to EPA and DHA, and effects on mitochondrial function and apoptosis, caspase-3 activation, gene expression and drug toxicity were measured.
Exposure to EPA and DHA induced apoptosis and increased sensitivity to bortezomib in MM cells.
Importantly, they did not affect viability of normal human peripheral mononuclear cells…
Our study suggests that EPA and DHA induce selective cytotoxic effects in MM and increase sensitivity to bortezomib and calls for further exploration into a potential application of these n-3 polyunsaturated fatty acids in the therapy of MM…”
“The self-renewal and differentiation of hematopoietic stem cells (HSCs) in bone marrow are essential to replenish all blood cell types, but how this process is influenced by diet remains largely unclear.
Here we show that a diet rich in fish oils promotes self-renewal of HSCs and extramedullary hematopoiesis. Chronic intake of a fish oil-rich diet increases the abundance of HSCs, alters the hematopoietic microenvironment, and, intriguingly, induces the expression of matrix metalloproteinase 12 (MMP12) in the bone marrow.
Pointing to a direct effect of fish oil on MMP12 expression, omega-3 polyunsaturated fatty acids induce the expression of MMP12 in a dose-dependent manner in bone marrow cells…
Thus, a fish oil-rich diet promotes hematopoiesis in the bone marrow and spleen, in part via the activity of MMP12. Taken together, these data provide new insights into diet-mediated regulation of hematopoiesis…”
“The aim of this study was to evaluate the benefits and risks of omega-3 fatty acid supplementation in patients with chronic kidney disease. A systematic search of articles in PubMed, Embase, the Cochrane Library, and reference lists was performed to find relevant literature.
All eligible studies assessed:
Standard mean differences with 95% confidence intervals for continuous data were used to estimate the effects of omega-3 fatty acid supplementation on renal function, as reflected by the serum creatinine clearance rate, proteinuria, the estimated glomerular filtration rate, and relative risk…
The results of this study suggest that omega-3 fatty acids significantly reduce the risk of ESRD and are associated with a lower risk of proteinuria…”
“Epidemiological studies on Greenland Inuits in the 1970s and subsequent human studies have established an inverse relationship between the ingestion of omega-3 fatty acids [C(20-22) ω 3 polyunsaturated fatty acids (PUFA)], blood levels of C(20-22) ω 3 PUFA, and mortality associated with cardiovascular disease (CVD).
C(20-22) ω 3 PUFA have pleiotropic effects on cell function and regulate multiple pathways controlling blood lipids, inflammatory factors, and cellular events in cardiomyocytes and vascular endothelial cells…
The hypolipemic, anti-inflammatory, anti-arrhythmic properties of these fatty acids confer cardioprotection…
The outcome of our analysis reveals that nonfish sources of ω 3 PUFA vary in their capacity to regulate blood levels of C(20-22) ω 3 PUFA and CVD risk factors…”
“The regular consumption of long-chain omega-3 polyunsaturated fatty acids (LCO3-PUFAs) results in general health benefits. The intake of LCO3-PUFAs has been reported to contribute to bone metabolism.
A total of 1865 female subjects (20–79 years old) were enrolled, and:
After adjustment for potential confounding factors, there were positive correlations between ALA, EPA and DHA intake and BMD.
According to the WHO diagnosis criteria for osteoporosis, in this population of normal and osteopenic women, the dietary intake of ALA was also significantly associated with BMD at the hip.
In normal women, the dietary intake of DHA was also significantly associated with BMD at the lumbar spine…
We highlight that the intake of LCO3-PUFAs is not significantly associated with BMD in osteoporotic women; however, the intake of LCO3-PUFAs seems to be positively associated with BMD at both the hips and the lumbar spine in normal and osteopenic women…”